Chiesi Farmaceutici
As of the edition of 20 October 2026, Chiesi Farmaceutici runs 36 drugs, 20 of them marketed; it is on route A at 5 targets and on route B at 10 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 4 company names in this family.
- Carbylan Therapeutics, Inc.: acquired in 2026; successor CHIESI FARMACEUTICI S.P.A.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 20 |
| Active | 3 |
| Went quiet | 6 |
| Stopped | 4 |
| Status not established | 3 |
| Total | 36 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Tacrolimus anhydrous | Ends 2028 (exclusivity) | 3 |
| Caffeine | none listed | 12 |
| Formoterol | none listed | 2 |
| Levofloxacin anhydrous | none listed | 0 |
| Octreotide | none listed | 5 |
| Glycopyrronium | none listed | 10 |
| Beclomethasone dipropionate | none listed | 3 |
| Deferiprone | Ends 2028 (exclusivity) | 0 |
| Metreleptin | Ended 2026 (computed from the first US licence) | 0 |
| Idebenone | none listed | 0 |
| Beclomethasone | none listed | 1 |
| Cangrelor | none listed | 0 |
| Clevidipine | none listed | 8 |
| Cysteamine | none listed | 0 |
| Lomitapide | Ends 2029 (exclusivity) | 1 |
| Pegunigalsidase alfa | Ends 2035 (computed from the first US licence) | 0 |
| Poractant alfa | Ended 2011 (computed from the first US licence) | 0 |
| Sebetralstat | Ends 2037 (patent) | 1 |
| Velmanase alfa | Ends 2035 (computed from the first US licence) | 0 |
| Birch triterpenes | Ends 2030 (exclusivity) | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 10 targets.
All 15 rows on route A or B
In the product15 company-target rows on route A or B; 12 are not shown here, and no score is.
See all 15 targets where Chiesi Farmaceutici needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Lungs and airways: 31 trials led
- Immune system: 21 trials led
- Inherited and neonatal: 21 trials led